{"id":"NCT01076010","sponsor":"AVEO Pharmaceuticals, Inc.","briefTitle":"An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).","officialTitle":"An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03","primaryCompletion":"2014-07","completion":"2014-07","firstPosted":"2010-02-25","resultsPosted":"2020-10-05","lastUpdate":"2020-10-05"},"enrollment":277,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Renal Cell Carcinoma"],"interventions":[{"type":"DRUG","name":"Tivozanib","otherNames":[]},{"type":"DRUG","name":"Sorafenib","otherNames":[]}],"arms":[{"label":"Sorafenib crossover to tivozanib.","type":"EXPERIMENTAL"},{"label":"First line tivozanib.","type":"EXPERIMENTAL"},{"label":"First line sorafenib.","type":"ACTIVE_COMPARATOR"}],"summary":"Open-label, multi-center extension treatment protocol to allow access to tivozanib and sorafenib for subjects who have participated on the AV-951-09-301 protocol. Eligible subjects who were randomized to receive sorafenib on AV-951-09-301 and had documented progression of disease will receive a tivozanib dose of 1.5 mg/day. Eligible subjects who were randomized to tivozanib or sorafenib in AV-951-09-301, and displayed clinical benefit and acceptable tolerability to treatment, will continue to receive tivozanib or sorafenib at the same dose and schedule as in AV-951-09-301.","primaryOutcome":{"measure":"Number of Days Subjects Received Treatment in Each Treatment Arm","timeFrame":"From enrollment to until all subjects discontinue (due to documented progressive disease [PD] or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902","effectByArm":[{"arm":"Sorafenib Crossover to Tivozanib","deltaMin":290,"sd":234.37},{"arm":"First Line Tivozanib.","deltaMin":325.3,"sd":137.79},{"arm":"First Line Sorafenib.","deltaMin":369.4,"sd":107.6}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":75,"countries":["United States","Bulgaria","Canada","Chile","Czechia","France","Hungary","India","Italy","Poland","Romania","Russia","Serbia","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.aveopharma.com"]},"adverseEventsSummary":{"seriousAny":{"events":49,"n":161},"commonTop":["Hypertension","Diarrhoea","Palmar-plantar erythrodysaesthesia syndrome","Fatigue","Asthenia"]}}